Boehringer set to make E.coli for clinical trials
Under the deal, Boehringer will manufacture a range of toxic materials including E.coli and other proteins for the DARPin pipeline.
The move the German firm’s recent expansion of its biomanufacturing facility and mammalian contract manufacturing services in Germany.
Simon Sturge, Boehringer’s corporate senior VP of biopharmaceuticals said: “This agreement reflects the strategy of Boehringer Ingelheim and its new brand Boehringer Ingelheim BioXcellence to be dedicated and committed to the development of highly innovative molecule platforms and projects.”
